Glycated Haemoglobin Testing Market to Reach USD 6.2 Billion by 2034

The global burden of diabetes is increasing at an unprecedented rate, and effective monitoring of blood glucose levels has become critical in managing this chronic disease. Among the most reliable tools in diabetes care is glycated haemoglobin (HbA1c) testing, which measures average blood sugar levels over two to three months. Unlike daily glucose monitoring, HbA1c testing provides a long-term perspective, making it a gold standard for diagnosing and managing diabetes.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73489

According to Exactitude Consultancy, the Glycated Haemoglobin Testing Market was valued at USD 3.5 billion in 2024 and is projected to reach USD 6.2 billion by 2034, growing at a CAGR of 6.0% between 2025 and 2034. This growth is fueled by the rising prevalence of diabetes, government initiatives for early detection, and technological advancements in diagnostic devices.

Market Overview
• Market Size (2024): USD 3.5 billion
• Forecast (2034): USD 6.2 billion
• CAGR (2025-2034): 6.0%

Key Growth Drivers
• Rising prevalence of type 2 diabetes and prediabetes worldwide.
• Growing demand for point-of-care (POC) testing devices in both clinical and homecare settings.
• Expansion of government screening programs for early detection of diabetes.
• Technological innovation in portable, digital, and automated HbA1c analyzers.

Key Challenges
• High testing costs in low- and middle-income countries.
• Lack of awareness and underdiagnosis of diabetes in rural populations.
• Variability in test accuracy across different devices and methods.

Major Players
Abbott Laboratories, Roche Diagnostics, Bio-Rad Laboratories, Siemens Healthineers, Tosoh Bioscience, Danaher Corporation (Beckman Coulter), EKF Diagnostics, Trinity Biotech, Arkray Inc., and Menarini Diagnostics.

Segmentation Analysis
By Product Type
• Laboratory-Based Analyzers
• Point-of-Care (POC) Devices
• Consumables (Reagents, Kits, Cartridges)
• Others

By Technology
• Ion-Exchange High-Performance Liquid Chromatography (HPLC)
• Immunoassay
• Enzymatic Assay
• Boronate Affinity Chromatography
• Others

By End User
• Hospitals
• Diagnostic Laboratories
• Home Care Settings
• Research & Academic Institutes

By Application
• Diabetes Diagnosis
• Diabetes Monitoring
• Prediabetes Screening
• Clinical Research

Segmentation Summary:
POC devices are experiencing the fastest adoption due to their convenience and immediate results, making them suitable for both hospital and home-based care. HPLC remains the gold standard for laboratory accuracy, while immunoassay and enzymatic technologies are expanding accessibility.

Explore Full Report here: https://exactitudeconsultancy.com/reports/73489/glycated-haemoglobin-testing-market

Regional Analysis
North America
• Largest market in 2024, led by the U.S.
• High diabetes prevalence and favorable insurance coverage drive adoption.
• Strong presence of leading diagnostic companies accelerates market growth.
Europe
• Germany, France, and the UK dominate adoption.
• Government policies emphasize early screening to reduce diabetes-related healthcare costs.
• Expanding use of POC analyzers in community healthcare centers.
Asia-Pacific
• Expected to register the fastest CAGR through 2034.
• China and India represent the largest diabetes patient pools globally.
• Rising healthcare investments and awareness campaigns boost adoption.
Middle East & Africa
• Growing prevalence of diabetes in GCC nations supports market expansion.
• Limited infrastructure and affordability challenges remain in many African countries.
Latin America
• Brazil and Mexico lead regional adoption.
• Growing private healthcare sector and urbanization drive demand for advanced testing.
Regional Summary:
North America leads in market value, but Asia-Pacific is the fastest-growing region, fueled by large patient populations and increasing investments in healthcare infrastructure. Europe continues steady growth, while Latin America and the Middle East are gradually expanding as awareness and affordability improve.

Market Dynamics
Growth Drivers
1. Rising diabetes prevalence, with millions of undiagnosed cases worldwide.
2. Expansion of home-based and portable HbA1c testing solutions.
3. Integration of digital connectivity and data management into analyzers.
4. Favorable government initiatives for preventive screening.

Key Challenges
1. High cost of advanced testing devices and consumables.
2. Limited patient awareness in rural and underserved regions.
3. Variability in test accuracy across device types.

Latest Trends
• Launch of AI-enabled analyzers for improved accuracy and automated reporting.
• Increasing focus on affordable and compact POC analyzers for emerging markets.
• Use of HbA1c testing in clinical research for evaluating new diabetes drugs.
• Integration with cloud-based patient management platforms.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=73489

Competitive Landscape
Major Players
• Abbott Laboratories
• Roche Diagnostics
• Bio-Rad Laboratories
• Siemens Healthineers
• Tosoh Bioscience
• Danaher Corporation (Beckman Coulter)
• EKF Diagnostics
• Trinity Biotech
• Arkray Inc.
• Menarini Diagnostics

Competitive Dynamics
The market is competitive, with global leaders focusing on expanding their product portfolios and launching POC analyzers for greater accessibility. Partnerships with healthcare providers and governments are helping scale adoption in both developed and emerging economies. Emerging players are focusing on cost-effective and portable devices to capture opportunities in Asia-Pacific and Latin America.

Conclusion
The Glycated Haemoglobin Testing Market is projected to grow steadily, rising from USD 3.5 billion in 2024 to USD 6.2 billion by 2034, at a CAGR of 6.0%.

• Point-of-care analyzers are driving growth due to convenience and faster diagnosis.
• North America leads adoption, while Asia-Pacific emerges as the fastest-growing region.
• Innovations such as AI-enabled, digital, and portable testing devices are shaping the competitive landscape.

With the rising global diabetes burden and increasing emphasis on early diagnosis, HbA1c testing is poised to become an even more critical tool in managing the disease. The next decade will see broader access, improved accuracy, and smarter technologies ensuring better patient outcomes worldwide.

This report is also available in the following languages : Japanese (グリコヘモグロビン検査市場), Korean (당화혈색소 검사 시장), Chinese (糖化血红蛋白检测市场), French (Marché des tests d'hémoglobine glyquée), German (Markt für Tests auf glykiertes Hämoglobin), and Italian (Mercato dei test dell'emoglobina glicata), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/73489/glycated-haemoglobin-testing-market#request-a-sample

Our More Reports:

Immune Checkpoint Inhibitors Market
https://exactitudeconsultancy.com/reports/72923/immune-checkpoint-inhibitors-market

Coronavirus Preventive Vaccines Market
https://exactitudeconsultancy.com/reports/72924/coronavirus-preventive-vaccines-market

Prefilled Syringe Fill Finish Manufacturing Market
https://exactitudeconsultancy.com/reports/72925/prefilled-syringe-fill-finish-manufacturing-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.